Vaccine. 2016 Apr 12. pii: S0264-410X(16)30104-9. doi: 10.1016/j.vaccine.2016.03.107. [Epub ahead of print]
Pneumococcal disease is a major cause of morbidity and mortality in young children, particularly in the developing world. Vaccines are a critical strategy for protecting children from pneumococcal disease and licensed pneumococcal conjugate vaccines (PCVs) are having a significant impact on invasive pneumococcal disease and pneumococcal pneumonia throughout the world. Currently available PCVs do not, however, cover all pneumococcal serotypes and are complicated and relatively expensive to manufacture. While new PCV development is focused on either higher valency or more inherent affordability for developing countries, new vaccines are needed that offer serotype-independent protection. Vaccines containing proteins that are common to all pneumococcal serotypes could provide broad protection to children worldwide. Protein subunit and whole cell vaccines have advanced into Phase 1 and 2 clinical trials but face considerable challenges before they can become licensed and widely distributed.
Copyright © 2016. Published by Elsevier Ltd.
Infant vaccination; Nasopharyngeal carriage; Pneumococcal conjugate vaccine; Protein vaccine; Streptococcus pneumoniae
[PubMed - as supplied by publisher]